Correction  by unknown
CORRECTIONS Corrections
In the article by Anderson JL, Adams CD, Antman EA, et al. “ACC/AHA 2007 Guidelines for the Management of
Patients With Unstable Angina/Non–ST-Elevation Myocardial Infarction: A Report of the American College of
Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002
Guidelines for the Management of Patients With Unstable Angina/Non–ST-Elevation Myocardial Infarction),” which
appeared in the August 14, 2007, online issue of the journal (J Am Coll Cardiol 2007;50:e1–157), the following corrections
are necessary:
● On multiple pages: Replace “calcium antagonist(s)” with “calcium channel blocker(s)” at all occurrences. These are
as follows:
X page e36: Class IIa Recommendation 4; Class IIb Recommendations 1 and 2; Class III Recommendation 3;
body of Table 12;
X page e43: title of Table 16;
X page e93: first column of Table 22;
X page e113: Class I Recommendations 1, 2, and 3; Class IIa Recommendation 2;
X page e114: Class IIb Recommendation; left column, first paragraph under “6.6.1. Coronary Artery Spasm
With Cocaine Use”; right column, line 6;
X page e115: left column, second paragraph;
X page e116: right column, last paragraph;
X page e117: left column, first paragraph; and
X page e118: right column, last paragraph.
● On page e38, Table 13: In the first sentence of the footnote, add “of UFH” after “50 to 60 U per kg.”
● On page e46, Figure 7 caption: Delete “B” from first sentence so that parenthetical wording is “e.g., Boxes B1 and
B2.”
● In Table 18, page e68:
 For the PURSUIT row: The GP IIb/IIIa n should be 670/4722; the GP IIb/IIIa percentage should be 14.2*;
the ARR percentage should be 1.5; the RR should be 0.90; the 95% CI should be 0.82 to 1.00; and the p
should be 0.04.
 For the ISAR-REACT (ACS) row: The 95% CI should be 0.57 to 0.97.
 For the All ACS trials row: The GP IIb/IIIa n should be 1726/16 668; the GP IIb/IIIa percentage should be
10.4; the ARR percentage should be 1.3; the RR should be 0.86; and the 95% CI should be 0.81 to 0.93.
 For the All PCI trials and ACS trials row: The GP IIb/IIIa n should be 2134/24 274; the GP IIb/IIIa
percentage should be 8.8; the ARR percentage should be 1.7; the RR should be 0.83; and the 95% CI should
be 0.83 to 0.84.
● On page e94, right column, second paragraph, line 4: Change “nonrandomized” to “randomized” so that sentence
reads “In contrast, a meta-analysis of randomized trials of early (less than 14d) initiation . . . .”
These changes have been made to the online version of the article.
doi:10.1016/j.jacc.2007.09.013
In the article by Anderson JL, Adams CD, Antman EA, et al. “ACC/AHA 2007 Guidelines for the Management of
Patients With Unstable Angina/NonST-Elevation Myocardial Infarction—Executive Summary: A Report of the
American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to
Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non–ST-Elevation Myocardial
Infarction),” which appeared in the August 14, 2007, issue of the journal (J Am Coll Cardiol 2007;50:652–726), the
following corrections should be made:
● On multiple pages: Replace “calcium antagonist(s)” with “calcium channel blocker(s)” at all occurrences. These are
as follows:
X page 659: Class IIa Recommendation 4, Class IIb Recommendation 1;
X page 660: Class IIb Recommendation 2 (top of left column), Class III Recommendation 3;
X page 669: Class I Recommendations 1, 2, and 3, Class IIa Recommendation 2, and Class IIb Recommen-
dation in “Cocaine and Methamphetamine Users” Section;
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X page 704, right column: first paragraph under “Pathophysiology and Presentation,” first paragraph under
“Treatment”; and
X page 705, left column: first paragraph, last paragraph; right column: first paragraph, last paragraph.
● On page 673, left column, first paragraph: Delete phrase “with increasing risk score” from the second-to-last line
so that sentence reads “. . . platelet GP IIb/IIIa inhibition (43), and an invasive strategy (44).”
● On page 675, left column, under “Cardiac Biomarkers of Necrosis and the Redefinition of AMI”: Delete the word
“biomarker” so that the sentence reads “Favorable features of biomarkers of necrosis are high concentrations . . . .”
● On page 678, left column, second paragraph under “Early Hospital Care”: Change “and” to “and/or” so that
sentence reads “. . . a GP IIb/IIIa receptor antagonist, and/or a thienopyridine (i.e., clopidogrel; initiation may be
deferred until a revascularization decision is made).”
● On page 680, Figure 6 caption: Delete “B” from first sentence so that parenthetical wording is “e.g., Boxes B1 and
B2.”
● On page 680, right column, last line: Insert a space between “formulations” and “than.”
● On page 681, left column, first paragraph: Change “has been” to “had been,” “implementation” to “implantation,”
and “which had been” to “but this has been” so that the sentence reads “ASA of 325 mg per day had been
recommended for 1 month after bare-metal stent implantation and 3 to 6 months after drug-eluting stent
implantation, but this has been modified to an initial dose range of 162 to 325 mg per day based on the risk of
excess bleeding with higher doses and an update of current evidence of outcomes after PCI (Table 6, Fig. 9).”
● On page 683, Table 6: In the Ticlopidine row, add the phrase “(duration same as clopidogrel)” after “MD of 250
mg orally twice daily” in both the “After PCI” and “At Hospital Discharge” columns.
● On page 684, Table 6: In the Abciximab row, “meg” should be “mcg.”
● On page 684, Table 6: In the first sentence of the footnote, add “of UFH” after “50 to 60 U per kg.”
● On page 692, left column, first line: Change “conformation” to “conformational” so that sentence reads as follows:
“When platelets are activated by a number of mechanisms, their GP IIb/IIIa cell membrane receptors undergo a
conformational change that increases receptor affinity for fibrinogen (168).”
● On page 694, right column, middle of third paragraph: Change “lower-risk” to “intermediate-risk” and delete “,
troponin-negative” and “, troponin-positive” so that sentence reads “. . . either an intravenous GP IIb/IIa inhibitor
or clopidogrel should be added to ASA and anticoagulant therapy before diagnostic angiography (upstream) for
intermediate-risk patients, and that both should be given before angiography for high-risk patients (Class I
recommendation).”
● On page 695, left column, first line: Delete “urgent” so that sentence reads “The first group consists of patients
requiring angiography/revascularization urgently because of ongoing ischemic symptoms or hemodynamic or
rhythm instability.”
● On page 695, right column, second paragraph: Delete “routine use of clopidogrel in the conservative arm” so that
sentence reads “Proposed explanations for the lack of incremental benefit with an invasive strategy include the high
rate of revascularization in the selective invasive therapy arm (47%), more aggressive medical therapy (statins,
clopidogrel) in both arms, and limited power owing to the relatively low rate of hard end points (195).”
● On page 697, right column, first paragraph: Add the following sentence to the end of the paragraph: “Coronary
CT angiography now offers noninvasive imaging of the coronary arteries (88,89).”
● In Figure 8, page 682: Add “Class I” inside the parentheses (before LOE) after “duration of hospitalization” and
after “at physician’s discretion.”
● In Table 8, page 693:
 For the PURSUIT row: The GP IIb/IIIa n should be 670/4722; the GP IIb/IIIa percentage should be 14.2*;
the ARR percentage should be 1.5; the RR should be 0.90; the 95% CI should be 0.82 to 1.00; and the p
should be 0.04.
 For the ISAR-REACT (ACS) row: The 95% CI should be 0.57 to 0.97.
 For the All ACS trials row: The GP IIb/IIIa n should be 1726/16 668; the GP IIb/IIIa percentage should be
10.4; the ARR percentage should be 1.3; the RR should be 0.86; and the 95% CI should be 0.81 to 0.93.
 For the All PCI trials and ACS trials row: The GP IIb/IIIa n should be 2134/24 274; the GP IIb/IIIa
percentage should be 8.8; the ARR percentage should be 1.7; the RR should be 0.83; and the 95% CI should
be 0.83 to 0.84.
An updated version of the table is presented below.
doi:10.1016/j.jacc.2007.09.012
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